RT Journal Article
SR Electronic
T1 Quantitative G6PD point-of-care test can be used reliably on cord blood to identify male and female newborns at increased risk of neonatal hyperbilirubinaemia: a mixed method study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.03.22277173
DO 10.1101/2022.07.03.22277173
A1 Germana Bancone
A1 Mary Ellen Gilder
A1 Elsie Win
A1 Gornpan Gornsawun
A1 Penporn Penpitchaporn
A1 Paw Khu Moo
A1 Laypaw Archasuksan
A1 Nan San Wai
A1 Sylverine Win
A1 Ko Ko Aung
A1 Ahmar Hashmi
A1 Borimas Hanboonkunupakarn
A1 Francois Nosten
A1 Verena I Carrara
A1 Rose McGready
YR 2022
UL http://medrxiv.org/content/early/2022/07/05/2022.07.03.22277173.abstract
AB Introduction New point-of-care (POC) quantitative G6PD testing devices developed to provide safe radical cure for P. vivax malaria may be used to diagnose G6PD deficiency in newborns at risk of severe neonatal hyperbilirubinaemia, improving clinical care, and preventing related morbidity and mortality.Methods We conducted a mixed-methods study analyzing technical performance and usability of the “STANDARD G6PD” Biosensor when used by trained midwives on cord blood samples at two rural clinics on the Thailand-Myanmar border.Results In 307 cord blood samples, the Biosensor had a sensitivity of 1.000 (95%CI 0.859-1.000) and a specificity of 0.993 (95% CI 0.971-0.999) as compared to gold standard spectrophotometry to diagnose G6PD deficient newborns using a receiving operator characteristic (ROC) analysis-derived threshold of ≤4.8IU/gHb. The Biosensor had a sensitivity of 0.640 (95%CI 0.426-0.813) and specificity of 0.954 (95%CI: 0.819-0.981) for 30-70% activity range in females using ROC analysis-derived range of 4.9 to 9.9IU/gHb. These thresholds allowed identification of all G6PD deficient neonates and 80% of female neonates with intermediate phenotypes.Need of phototherapy treatment for neonatal hyperbilirubinaemia was higher in neonates with deficient and intermediate phenotypes as diagnosed by either reference spectrophotometry or Biosensor.Focus group discussions found high levels of learnability, willingness, satisfaction, and suitability for the Biosensor in this setting. The staff valued the capacity of the Biosensor to identify newborns with G6PD deficiency early (“We can know that early, we can counsel the parents about the chances of their children getting jaundice”) and at the POC, including in more rural settings (“Because we can know the right result of the G6PD deficiency in a short time. Especially for the clinic which does not have a lab”). Conclusions: The Biosensor is a suitable tool in this resource-constrained setting to identify newborns with abnormal G6PD phenotypes at increased risk of neonatal hyperbilirubinaemia.WHAT IS ALREADY KNOWN ON THIS TOPIC G6PD deficiency is one of the major risk factors for severe neonatal hyperbilirubinaemia and kernicterus.Accurate diagnosis of newborns with G6PD deficient and intermediate phenotypes is currently possible only in tertiary hospitals with laboratory facilities.WHAT THIS STUDY ADDS The G6PD quantitative point-of-care diagnostic device tested can be used in cord blood to provide a highly accurate identification of G6PD deficient newborns; it can also identify intermediate phenotypes in female newborns with good accuracy.The device showed good usability characteristics in a resource-constrained setting when used by clinical staff.HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Use of quantitative point-of-care G6PD diagnostics at birth can provide a timely diagnosis of G6PD status to support better perinatal care and avert morbidity and mortality in resource-constrained settings.Reliable point-of-care G6PD diagnostics can become a useful tool for universal newborn screening.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by a grant to GB by the Wellcome Trust Institutional Translational Partnership Awards: Thailand Major Overseas Programme (WT-iTP-2019/004). SMRU is supported by the Wellcome Trust [grant 220111]. For the purpose of Open Access, the authors have applied a CC BY public copyright licence to any author accepted manuscript version arising from this submission. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Oxford Tropical Research Ethics Committee, UK (OxTREC 532-19), the Mahidol University Faculty of Tropical Medicine Ethics Committee, Thailand (TMEC 19-048, MUTM 2019-080-02) and the Tak Province Border Community Ethics Advisory Board (TCAB201904).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified participant data are available from the Mahidol Oxford Tropical Medicine Data Access Committee upon request from this link: https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/datasharing.The study was supported by a grant to GB by the Wellcome Trust Institutional Translational Partnership Awards: Thailand Major Overseas Programme (WT-iTP-2019/004). SMRU is supported by the Wellcome Trust [grant 220111]. For the purpose of Open Access, the authors have applied a CC BY public copyright licence to any author accepted manuscript version arising from this submission. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.